← All candidates
Eight insider buys in the last year — $207.2K in all.
32 filings on record.
RZLTRezolute, Inc.
NasdaqCM · Healthcare · $406.35M
$3.95
+0.52% today
Eight insider buys in the last year — $207.2K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 8 buys◆ 6 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what RZLT ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$406.35M
Float
60.5M
63% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Kim Young-Jin
Bought $4.00M on Jun 13 — 1,230,769 sh @ $3.25, held indirect, 15% of their stake.
1 of 1 position beat the S&P
CFO
Evans Daron
Bought $70.6K on Dec 15 — 40,000 sh @ $1.77, held direct, 9.6% of their stake.
0 of 1 position beat the S&P
CEO
Elam Nevan C
Bought $50.9K on Dec 15 — 32,000 sh @ $1.59, held direct, 5.0% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
3 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
27 more transactions on Pro →Context
Wall St
$7.67 avg target
+94.1% vs today · 9 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 3 quarters beat
Q4 '25−$0.22 act−$0.04
Q3 '25−$0.18 act+$0.08
Q2 '25−$0.26 act−$0.03
Coverage
Positive Signs As Multiple Insiders Buy Rezolute StockSimply Wall St. · 06-10RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?Zacks · 06-04Rezolute’s stock up on interim Phase III tumour HI dataClinical Trials Arena · 06-03Rezolute Stock Gains After FDA Meeting on Ersodetug Program UpdateZacks · 03-25
The file stays open
32 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice